- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Bristol-Myers Squibb Co. (BMY)
by latest | most commented
-
P/E - Value Plays or Value Traps?
-
Alternate Short Strategy: Put Protection for Less (Part III)
-
Healthcare: Branded Pharma Out, Diagnostics / Generics In
-
2009 Fortune 40 Best Stocks for Retirement: Part II
-
Comparing Medicine’s Cost and Effectiveness
-
Pharmaceutical Dollar Rationing by Results
-
Hedge Fund Moore Stakes Out Energy Bets
-
Preview from Europe: Important Week Ahead for Economic Data
-
FDA Calendar Updates: AZN, BMY, OSUR, CPD, INSM, HLUKY
-
Medarex's Vaccine-Like Prostate Cancer Treatment Shows Great Promise
-
51 Option Ideas for Bears
-
FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex
-
Fortune's 40 Best Stocks to Retire On
-
Amgen's Better than Expected Portfolio Outlook
-
Audit Integrity Updates High Risk Company WatchList
-
Canadian Fund Portfolio Update
-
Nine Value Companies to Watch
-
30 Attractive Companies Under $30: Fidelity's Low Priced Stock Fund Part II
-
Market Recovery Means Learning from Our Mistakes
-
Preview from Europe: U.S. Jobs Data Due; Brown Reshuffles the Deck
-
Preview from Europe: Stocks Consolidate, But Financials Hit a Speed Bump
-
Why We're Cautious on The Medicines Company
-
Preview from Europe: Commodities Cheer Stocks On
-
Wall Street Breakfast: Must-Know News
-
FDA, Clinical Trial Updates: MAP Pharma, Cytokinetics, Hemispherx Post Big Gains
-
Is Mylan Short Base Rising over Uncertainties in Healthcare?
-
Big Pharma Maintains Illusion of Innovation
-
Why Is Eli Lilly's CEO on the Media Offensive?
-
High Yield Blue Chips Set to Rally?
-
AstroZeneca: Brilinta News Not a Panacea
-
Vanda Pharmaceuticals: Tomorrow's Headline Stock
-
Pharmaceutical Stocks Remain a Buy
-
Wall Street Breakfast: Must-Know News
-
Preview from Europe: Pigs Scare the Market Bulls
-
Earnings Preview: Bristol Myers Squibb
-
FDA Calendar Updates: Diabetes
-
Thoughts on Active Trading vs. Buy and Hold
-
IHE: Large-Cap Pharma Continues to Blow Away the S&P 500
-
Trade Deficit Keeps Improving
-
Bristol-Myers Squibb: An Attractive Value
-
Markets See Record 4 Week Gains